Rapt Therapeutics (RAPT)
(Delayed Data from NSDQ)
$7.80 USD
-0.10 (-1.27%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $7.81 +0.01 (0.13%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Rapt Therapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -116.80 | -83.84 | -69.20 | -52.89 | -43.00 |
Depreciation/Amortization & Depletion | -4.52 | 0.75 | 2.27 | 1.62 | 1.33 |
Net Change from Assets/Liabilities | 5.50 | -1.34 | -4.30 | 2.34 | 4.13 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 18.77 | 13.65 | 10.21 | 8.44 | 2.06 |
Net Cash From Operating Activities | -97.05 | -70.77 | -61.03 | -40.49 | -35.47 |
Property & Equipment | -1.13 | -0.85 | -0.76 | -0.40 | -0.84 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 105.26 | -44.65 | -80.59 | -87.04 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 104.13 | -45.49 | -81.35 | -87.44 | -0.84 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 1.45 | 131.18 | 141.48 | 75.46 | 49.90 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 1.45 | 131.18 | 141.48 | 75.46 | 49.90 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 8.53 | 14.92 | -0.89 | -52.47 | 13.59 |
Cash at Beginning of Period | 38.95 | 24.03 | 24.92 | 77.38 | 63.80 |
Cash at End of Period | 47.48 | 38.95 | 24.03 | 24.92 | 77.38 |
Diluted Net EPS | -3.05 | -2.58 | -2.53 | -2.19 | -9.89 |
Fiscal Year End for Rapt Therapeutics falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -116.80 | -85.92 | -54.55 | -29.27 |
Depreciation/Amortization & Depletion | NA | -4.52 | -3.62 | -2.38 | -1.14 |
Net Change from Assets/Liabilities | NA | 5.50 | 6.49 | 0.68 | 7.13 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 18.77 | 13.76 | 8.85 | 4.68 |
Net Cash From Operating Activities | NA | -97.05 | -69.29 | -47.41 | -18.60 |
Property & Equipment | NA | -1.13 | -1.06 | -0.99 | -0.76 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 105.26 | 84.55 | 58.74 | 26.07 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 104.13 | 83.49 | 57.75 | 25.31 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 1.45 | 0.99 | 0.88 | 0.12 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 1.45 | 0.99 | 0.88 | 0.12 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | 8.53 | 15.19 | 11.22 | 6.82 |
Cash at Beginning of Period | NA | 38.95 | 38.95 | 38.95 | 38.95 |
Cash at End of Period | NA | 47.48 | 54.14 | 50.16 | 45.77 |
Diluted Net EPS | NA | -0.81 | -0.82 | -0.66 | -0.76 |